Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸ P-TRG 2021 : 2021-09-11±³À°ÀÏÀÚ : 2021-09-11
±³À°Àå¼Ò : ¼¿ï ÄÚ¿¢½º 3F, ÄÁÆÛ·±½º·ë(³²) E
±³À°ÁÖÁ¦ :
P-TRG 2021ÁÖÃÖ±â°ü : ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¼ÒÆÇ-Ç÷Àü¿¬±¸È¸
´ã´çÀÚ : Á¤ÀºÇý
¿¬¶ôó : 02-582-8212
À̸ÞÀÏ :
grace@kscvi.org ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í -Á¤È¸¿ø ¹«·á µî·Ï -Àü¹®ÀÇ/°³¿øÀÇ/ÀϹÝÀÇ: 60,000 -ÀüÀÓÀÇ/Àü°øÀÇ: 30,000 -°£È£»ç/ÀÇ·á±â»ç/ÀÇ´ë»ý/±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ/ÀÓ»óº´¸®»ç/Àǹ«±â·Ï»ç: 20,000 -»ê¾÷ü/±âŸ: 120,000 * ÇöÀåµî·Ï¸¸ °¡´ÉÇÕ´Ï´Ù
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-11 E 09:00~09:10 Prophylactic Anticoagulation in Patients with COVID-19: ACTION, INSPIRATION 5 ÀÌÀåÈÆ(°æºÏÀÇ´ë)
±³À°½Ã°£ 09-11 E 09:10~09:20 Uniform De-escalation of a Potent P2Y12 Inhibitor: TALOS-AMI ¹Ú¸¸¿ø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09-11 E 09:20~09:30 Antithrombotics in Patients undergoing TAVR: ATLANTIS ±èÁ¤¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-11 E 09:30~09:40 Antithrombotics in Patients with PAD: VOYAGER-PAD ¿øÈ£¿¬(Áß¾ÓÀÇ´ë)
Åä·Ð 09-11 E 09:40~10:00 Discussion ()
ÈÞ½Ä 09-11 10:00~10:10 Break ()
±³À°½Ã°£ 09-11 E 10:10~10:20 In Depth Review of HOST-EXAM °ÁöÈÆ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09-11 E 10:20~10:30 Rationale of Clopidogrel Monotherapy °¹Î±Ô(°æ»óÀÇ´ë)
±³À°½Ã°£ 09-11 E 10:30~10:40 Clopidogrel Monotherapy in CHIP ¹Ú¿ëÈÖ(°æ»óÀÇ´ë)
±³À°½Ã°£ 09-11 E 10:40~10:50 DAPT in CHIP ÃÖ±âÈ«(¼º±Õ°üÀÇ´ë)
Åä·Ð 09-11 E 10:50~11:10 Discussion ()
ÈÞ½Ä 09-11 11:10~11:20 Coffee Break ()
±³À°½Ã°£ 09-11 E 11:20~11:35 Clopidogrel vs. Ticagrelor: How to Use Common Data Model in Clinical Research À¯½ÂÂù(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-11 E 11:35~11:50 Ethnic Difference of Thrombogenicty Á¤¿µÈÆ(°æ»óÀÇ´ë)
±³À°½Ã°£ 09-11 E 11:50~12:05 Prognostic Implication of Platelet Reactivity between East Asian vs. Westerner À̽ÂÁØ(¿¬¼¼ÀÇ´ë)
Åä·Ð 09-11 E 12:05~12:30 Discussion ()
±âŸ 09-11 E 12:30~12:50 P-TRG ÃÑȸ ()
±³À°½Ã°£ 09-11 E 12:50~13:10 SMART-ATTEMPT: Prasugrel vs Clopidogrel in Elective PCI for Complex Lesion ¼Û¿µºó(¼º±Õ°üÀÇ´ë)
Åä·Ð 09-11 E 13:10~13:30 Discussion ()
ÈÞ½Ä 09-11 13:30~13:40 Break ()
±³À°½Ã°£ 09-11 E 13:40~13:55 Imaging Study is the Best Guidance À±ÇõÁØ(°è¸íÀÇ´ë)
±³À°½Ã°£ 09-11 E 13:55~14:10 Physiological Optimization Has the Paramount Importance ÀÌÁÖ¸í(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 09-11 E 14:10~14:25 Era of Microcirculation Is Upcoming À̺´±Ç(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 09-11 E 14:25~14:40 Bad Blood Is the Real Matter Á¤¿µÈÆ(¼¿ïÀÇ´ë)
Åä·Ð 09-11 E 14:40~15:10 Discussion ()
ÈÞ½Ä 09-11 15:10~15:20 Coffee Break ()
±³À°½Ã°£ 09-11 E 15:20~15:30 Prognostic Implication of Platelet Reactivity according to Complex PCI À̱¤¹Î(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 09-11 E 15:30~15:40 Prognostic Implication of Platelet Reactivity according to Gender ±è¼öÁø(°í½ÅÀÇ´ë)
±³À°½Ã°£ 09-11 E 15:40~15:50 Prognostic Implication of Platelet Reactivity according to CKD Classification ÀÌ»ó¿±(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 09-11 E 15:50~16:00 Prognostic Implication of Platelet Reactivity according to LV Systolic Function Çѵ¿ÈÆ(ÇѸ²ÀÇ´ë)
Åä·Ð 09-11 E 16:00~16:20 Discussion ()
ÈÞ½Ä 09-11 16:20~16:30 Break ()
±³À°½Ã°£ 09-11 E 16:30~16:40 Clinical Impact of High On-treatment Platelet Reactivity in Patients with Prolonged Clopidogrel Therapy ±è¼¼ÈÆ(¼º³²½ÃÀÇ·á¿ø)
±³À°½Ã°£ 09-11 E 16:40~16:50 Benefits of Prasugrel in Korean Patients õ¹Î±¸(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09-11 E 16:50~17:00 Drug Adherence and Clinical Outcome in Patients Treated with DES ¹èÀç¼®(°æ»óÀÇ´ë)
±³À°½Ã°£ 09-11 E 17:00~17:10 Pitfalls of Current Bleeding and Ischemic Risk Scales ±èÈ«³â(°æºÏÀÇ´ë)
Åä·Ð 09-11 E 17:10~17:30 Discussion ()